A case study of development, validation, and acceptance of a non-animal method for assessing human vaccine potency

Procedia in Vaccinology

Volumn 5, Issue , 2011, Pages 184-191

  Descamps, Johan ^a   Giffroy, Didier ^a   Remy, Eric ^a   Mortiaux, Frederic ^a   Mareschal, Jean Claude ^a   Ponsar, Cecile ^a   Duchene, Michel ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Hepatitis B vaccine; In vitro test; Non animal methods; Potency test

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; VALIDATION STUDY;

EID: 84555190321     PISSN: None     EISSN: 1877282X     Source Type: Journal    
DOI: 10.1016/j.provac.2011.10.018     Document Type: Article

References (10)

1. Method of Analysis. Biological assays: Assay of hepatitis B vaccine (rDNA) [ch. 2.7.15]. In: European Pharmacopoeia, 67th ed. Strasbourg, France: European Department for the Quality of Medicines & HealthCare (EDQM), Council of Europe, 2011.
2. WHO Expert Committee on Biological Standardization. Requirements for hepatitis B vaccines made by recombinant DNA techniques. In: WHO Technical Report Series, No. 786. Geneva: World Health Organization, 1989, 28. Available at: http://www.who.int/biologicals/publications/trs/en/.
3. European Pharmacopoeia. Monograph 1056. Hepatitis B vaccine (rDNA), Ph.Eur. 6th Edition. Strasbourg, France: European Department for the Quality of Medicines within the Council of Europe; 2008.
4. United States Pharmacopoeia- National Formulary. Monograph 88 Biological reactivity tests, in vivo'. United states Pharmacopoeial Convention,Inc. 12601 Twinbrook Parkway, Rockville, MD 20852,USA.
5. Finney DJ. Parallel line assays. In: Statistical Method in Biological Assay, 3rd ed. London: Charles Griffin & Company, 1978, 69-104.
6. Iwarson S., Tabor E., Thomas H.C., Goodall A., Waters J., Snoy P., et al. Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J Med Virol 1985, 16(1):89-96.
7. Waters J.A., Brown S.E., Steward M.W., Howard C.R., Thomas H.C. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res 1992, 22(1):1-12.
8. International Conference on Harmonisation (ICH). Guidance for Industry. Q2B Validation of Analytical Procedures: Methodology, 1996.
9. Giffroy D., Mazy C., Duchêne M. Validation of a new ELISA method for in vitro potency assay of hepatitis B-containing vaccines. Pharmeuropa Bio 2006, 1:7-14.
10. Descamps J, Mary A, Rommel E, Anhoury ML, De Neys R, Duchêne M. Release potency tests of hepatitis vaccines. In: Sesardic D, Brown F, Hendriksen CFM, editors. Alternatives to Animals in the Development and Control of Biological Products for Human and Veterinary Use. Meeting of the International Association of Biological Standardization. September 1998. London. Dev Biol Stand (Basel): Karger, 1999;100:289-94.